Steve Groshong
Concepts (323)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 15 | 2023 | 696 | 1.010 |
Why?
| | Lung | 26 | 2026 | 4141 | 0.650 |
Why?
| | Lung Diseases, Interstitial | 12 | 2017 | 675 | 0.550 |
Why?
| | Lung Diseases | 3 | 2023 | 787 | 0.390 |
Why?
| | Alveolitis, Extrinsic Allergic | 3 | 2023 | 96 | 0.390 |
Why?
| | Mucin-5B | 6 | 2018 | 234 | 0.390 |
Why?
| | Tomography, X-Ray Computed | 11 | 2023 | 2791 | 0.380 |
Why?
| | Biopsy | 9 | 2019 | 1093 | 0.380 |
Why?
| | Pulmonary Fibrosis | 6 | 2020 | 395 | 0.370 |
Why?
| | Fibroblasts | 6 | 2020 | 1039 | 0.290 |
Why?
| | Bleomycin | 3 | 2020 | 256 | 0.280 |
Why?
| | Interdisciplinary Communication | 1 | 2009 | 201 | 0.270 |
Why?
| | Bronchoscopy | 4 | 2018 | 228 | 0.240 |
Why?
| | Diagnosis, Differential | 9 | 2023 | 1518 | 0.230 |
Why?
| | Emergency Medical Technicians | 1 | 2006 | 40 | 0.230 |
Why?
| | Vaping | 1 | 2026 | 81 | 0.220 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 430 | 0.210 |
Why?
| | Apoptosis | 5 | 2026 | 2454 | 0.200 |
Why?
| | Machine Learning | 3 | 2019 | 596 | 0.200 |
Why?
| | Cysts | 2 | 2023 | 112 | 0.200 |
Why?
| | Acute Lung Injury | 2 | 2022 | 312 | 0.200 |
Why?
| | Anti-Asthmatic Agents | 1 | 2026 | 264 | 0.200 |
Why?
| | Birt-Hogg-Dube Syndrome | 1 | 2023 | 9 | 0.190 |
Why?
| | Peritoneal Neoplasms | 1 | 2004 | 104 | 0.190 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2023 | 36 | 0.190 |
Why?
| | Asthma | 3 | 2026 | 1805 | 0.190 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2023 | 37 | 0.190 |
Why?
| | Teratoma | 1 | 2004 | 124 | 0.190 |
Why?
| | Lung Injury | 1 | 2026 | 262 | 0.190 |
Why?
| | Inflammation | 6 | 2026 | 2920 | 0.170 |
Why?
| | Research Report | 1 | 2022 | 89 | 0.170 |
Why?
| | Cough | 2 | 2015 | 124 | 0.170 |
Why?
| | Middle Aged | 32 | 2026 | 36821 | 0.160 |
Why?
| | Bronchial Diseases | 2 | 2012 | 38 | 0.160 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2020 | 22 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 1005 | 0.150 |
Why?
| | Myofibroblasts | 2 | 2018 | 149 | 0.150 |
Why?
| | Glioma | 1 | 2004 | 432 | 0.150 |
Why?
| | Lung Neoplasms | 4 | 2018 | 2679 | 0.150 |
Why?
| | Biomarkers, Tumor | 4 | 2014 | 1339 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2020 | 475 | 0.140 |
Why?
| | Phenotype | 5 | 2015 | 3216 | 0.140 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2018 | 8 | 0.140 |
Why?
| | Common Variable Immunodeficiency | 1 | 2018 | 26 | 0.140 |
Why?
| | Epithelial Cells | 5 | 2026 | 1141 | 0.140 |
Why?
| | Dihematoporphyrin Ether | 1 | 2018 | 2 | 0.140 |
Why?
| | Humans | 49 | 2026 | 147293 | 0.140 |
Why?
| | Ovarian Neoplasms | 1 | 2004 | 599 | 0.130 |
Why?
| | Photochemotherapy | 1 | 2018 | 39 | 0.130 |
Why?
| | Photosensitizing Agents | 1 | 2018 | 42 | 0.130 |
Why?
| | Aged | 21 | 2026 | 26514 | 0.130 |
Why?
| | Sarcoidosis, Pulmonary | 2 | 2009 | 100 | 0.130 |
Why?
| | Sequence Analysis, RNA | 2 | 2017 | 443 | 0.130 |
Why?
| | Complement C3 | 1 | 2018 | 188 | 0.120 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2625 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 367 | 0.120 |
Why?
| | HLA-DQ beta-Chains | 1 | 2016 | 58 | 0.120 |
Why?
| | fas Receptor | 2 | 2018 | 91 | 0.120 |
Why?
| | Genetic Loci | 2 | 2016 | 272 | 0.110 |
Why?
| | HLA-DRB1 Chains | 1 | 2016 | 110 | 0.110 |
Why?
| | Case-Control Studies | 8 | 2018 | 3660 | 0.110 |
Why?
| | Male | 30 | 2026 | 73950 | 0.110 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2015 | 44 | 0.110 |
Why?
| | Genotype | 2 | 2018 | 1875 | 0.110 |
Why?
| | Genomics | 1 | 2021 | 839 | 0.110 |
Why?
| | Adenocarcinoma | 2 | 2018 | 928 | 0.110 |
Why?
| | Female | 30 | 2026 | 80076 | 0.100 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 50 | 0.100 |
Why?
| | Receptors, Bombesin | 1 | 2014 | 5 | 0.100 |
Why?
| | Genome-Wide Association Study | 3 | 2016 | 1496 | 0.100 |
Why?
| | Adult | 18 | 2026 | 41405 | 0.100 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2013 | 25 | 0.100 |
Why?
| | Carcinoma, Small Cell | 1 | 2014 | 173 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 252 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 1195 | 0.090 |
Why?
| | Animals | 15 | 2026 | 38410 | 0.090 |
Why?
| | Genetic Variation | 1 | 2018 | 995 | 0.090 |
Why?
| | Mucin 5AC | 1 | 2013 | 71 | 0.090 |
Why?
| | Collagen | 2 | 2012 | 460 | 0.090 |
Why?
| | Signal Transduction | 3 | 2026 | 5272 | 0.090 |
Why?
| | Immunohistochemistry | 6 | 2018 | 1730 | 0.090 |
Why?
| | Respiratory Function Tests | 3 | 2026 | 545 | 0.090 |
Why?
| | E2F1 Transcription Factor | 1 | 2012 | 68 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 63 | 0.090 |
Why?
| | Bronchi | 1 | 2013 | 263 | 0.090 |
Why?
| | Mice | 11 | 2022 | 18491 | 0.090 |
Why?
| | Up-Regulation | 2 | 2013 | 848 | 0.090 |
Why?
| | Cilia | 1 | 2013 | 173 | 0.090 |
Why?
| | Trachea | 1 | 2013 | 258 | 0.090 |
Why?
| | Disease Models, Animal | 5 | 2018 | 4604 | 0.080 |
Why?
| | Lipopolysaccharides | 2 | 2012 | 863 | 0.080 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2011 | 60 | 0.080 |
Why?
| | Algorithms | 1 | 2019 | 1868 | 0.080 |
Why?
| | Arthritis, Rheumatoid | 2 | 2012 | 1183 | 0.080 |
Why?
| | Genetic Markers | 3 | 2021 | 338 | 0.080 |
Why?
| | Pulmonary Medicine | 1 | 2011 | 78 | 0.080 |
Why?
| | beta Carotene | 1 | 2010 | 20 | 0.080 |
Why?
| | Peptides, Cyclic | 1 | 2012 | 273 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2015 | 2223 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2021 | 2017 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2015 | 2973 | 0.080 |
Why?
| | Coronavirus, Rat | 1 | 2009 | 1 | 0.080 |
Why?
| | Serum Amyloid A Protein | 1 | 2009 | 32 | 0.080 |
Why?
| | Pulmonary Alveoli | 2 | 2009 | 389 | 0.080 |
Why?
| | Virus Replication | 2 | 2009 | 521 | 0.070 |
Why?
| | Salivary Glands, Minor | 1 | 2009 | 10 | 0.070 |
Why?
| | Proteins | 1 | 2015 | 1024 | 0.070 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2009 | 20 | 0.070 |
Why?
| | Sjogren's Syndrome | 1 | 2009 | 37 | 0.070 |
Why?
| | Gammaherpesvirinae | 1 | 2009 | 45 | 0.070 |
Why?
| | Lymphoproliferative Disorders | 1 | 2009 | 59 | 0.070 |
Why?
| | Actinomycosis | 1 | 2008 | 5 | 0.070 |
Why?
| | Immunity, Innate | 2 | 2012 | 840 | 0.070 |
Why?
| | Toll-Like Receptor 2 | 1 | 2009 | 125 | 0.070 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2009 | 63 | 0.070 |
Why?
| | Gene Expression Profiling | 5 | 2016 | 1794 | 0.070 |
Why?
| | Hemorrhage | 1 | 2014 | 832 | 0.070 |
Why?
| | Societies, Medical | 2 | 2011 | 914 | 0.070 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2009 | 127 | 0.070 |
Why?
| | Scleroderma, Limited | 1 | 2008 | 5 | 0.070 |
Why?
| | Disease Progression | 4 | 2023 | 2890 | 0.070 |
Why?
| | Herpesviridae Infections | 1 | 2009 | 148 | 0.070 |
Why?
| | Prospective Studies | 6 | 2021 | 8164 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2012 | 1977 | 0.070 |
Why?
| | Colitis, Ischemic | 1 | 2007 | 5 | 0.060 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2007 | 47 | 0.060 |
Why?
| | Escherichia coli O157 | 1 | 2007 | 14 | 0.060 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2007 | 29 | 0.060 |
Why?
| | Foreign Bodies | 1 | 2008 | 110 | 0.060 |
Why?
| | Neoplasm Proteins | 1 | 2010 | 445 | 0.060 |
Why?
| | Autoantibodies | 2 | 2012 | 1513 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3448 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 342 | 0.060 |
Why?
| | Mesocricetus | 1 | 2026 | 52 | 0.060 |
Why?
| | Pneumonia | 2 | 2009 | 636 | 0.060 |
Why?
| | Cells, Cultured | 4 | 2020 | 4169 | 0.060 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 125 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2012 | 1132 | 0.060 |
Why?
| | Cricetinae | 1 | 2026 | 305 | 0.060 |
Why?
| | Missouri | 1 | 2006 | 67 | 0.060 |
Why?
| | Dietary Supplements | 1 | 2010 | 586 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2009 | 786 | 0.060 |
Why?
| | Ambulances | 1 | 2006 | 52 | 0.060 |
Why?
| | Influenza A virus | 1 | 2026 | 119 | 0.060 |
Why?
| | Promoter Regions, Genetic | 3 | 2018 | 1253 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2018 | 3153 | 0.050 |
Why?
| | Aged, 80 and over | 5 | 2021 | 8430 | 0.050 |
Why?
| | Gene Expression | 3 | 2017 | 1481 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1224 | 0.050 |
Why?
| | Coronavirus Infections | 1 | 2009 | 378 | 0.050 |
Why?
| | Retinoblastoma Protein | 1 | 2004 | 62 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2004 | 74 | 0.050 |
Why?
| | alpha-Fetoproteins | 1 | 2004 | 42 | 0.050 |
Why?
| | Autophagy | 1 | 2026 | 291 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 878 | 0.050 |
Why?
| | Biopsy, Needle | 2 | 2018 | 186 | 0.050 |
Why?
| | Linkage Disequilibrium | 2 | 2016 | 259 | 0.050 |
Why?
| | Hysterectomy | 1 | 2004 | 138 | 0.050 |
Why?
| | Smoking | 1 | 2010 | 1483 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2023 | 2080 | 0.050 |
Why?
| | Gene Frequency | 2 | 2015 | 498 | 0.050 |
Why?
| | Vital Capacity | 1 | 2023 | 293 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 2133 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2026 | 11947 | 0.040 |
Why?
| | Cohort Studies | 4 | 2017 | 6099 | 0.040 |
Why?
| | Pyridones | 1 | 2023 | 210 | 0.040 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 268 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2013 | 751 | 0.040 |
Why?
| | Young Adult | 4 | 2026 | 14437 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 3 | 2016 | 2458 | 0.040 |
Why?
| | Interleukin-10 | 2 | 2014 | 311 | 0.040 |
Why?
| | Biomarkers | 2 | 2026 | 4351 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 568 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2026 | 1368 | 0.040 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2004 | 648 | 0.040 |
Why?
| | Macrophages, Alveolar | 2 | 2014 | 377 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2014 | 975 | 0.030 |
Why?
| | Emergency Medical Services | 1 | 2006 | 691 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 82 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2018 | 67 | 0.030 |
Why?
| | Chronic Disease | 2 | 2018 | 1844 | 0.030 |
Why?
| | A549 Cells | 1 | 2018 | 75 | 0.030 |
Why?
| | Retrospective Studies | 6 | 2014 | 17560 | 0.030 |
Why?
| | Rats | 3 | 2011 | 5613 | 0.030 |
Why?
| | Adolescent | 4 | 2026 | 22825 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 800 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 776 | 0.030 |
Why?
| | Dogs | 1 | 2018 | 518 | 0.030 |
Why?
| | Down-Regulation | 1 | 2018 | 618 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 357 | 0.030 |
Why?
| | Pneumonectomy | 1 | 2018 | 167 | 0.030 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 51 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 643 | 0.030 |
Why?
| | ADAMTS9 Protein | 1 | 2015 | 5 | 0.030 |
Why?
| | Serpin E2 | 1 | 2015 | 5 | 0.030 |
Why?
| | Procollagen N-Endopeptidase | 1 | 2015 | 7 | 0.030 |
Why?
| | ADAMTS4 Protein | 1 | 2015 | 16 | 0.030 |
Why?
| | Phosphorylation | 1 | 2020 | 1721 | 0.030 |
Why?
| | Serpins | 1 | 2015 | 28 | 0.030 |
Why?
| | E-Selectin | 1 | 2015 | 61 | 0.030 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2015 | 36 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 6041 | 0.030 |
Why?
| | ROC Curve | 1 | 2017 | 626 | 0.030 |
Why?
| | ADAM Proteins | 1 | 2015 | 65 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2009 | 1172 | 0.030 |
Why?
| | NF-kappa B | 2 | 2009 | 676 | 0.030 |
Why?
| | Auscultation | 1 | 2015 | 4 | 0.030 |
Why?
| | Herpesviridae | 1 | 2015 | 21 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2015 | 90 | 0.030 |
Why?
| | Hemosiderin | 1 | 2014 | 2 | 0.030 |
Why?
| | Bleeding Time | 1 | 2014 | 5 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2007 | 2420 | 0.030 |
Why?
| | Cell Line | 2 | 2011 | 2832 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2015 | 104 | 0.030 |
Why?
| | Neutrophils | 2 | 2011 | 1135 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1720 | 0.030 |
Why?
| | Integrin alpha6 | 1 | 2013 | 9 | 0.030 |
Why?
| | Tetraspanin 24 | 1 | 2013 | 7 | 0.030 |
Why?
| | Cell Proliferation | 2 | 2013 | 2529 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2015 | 173 | 0.030 |
Why?
| | Thromboplastin | 1 | 2013 | 67 | 0.020 |
Why?
| | Fibrin | 1 | 2014 | 84 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 397 | 0.020 |
Why?
| | Neoplasms | 1 | 2009 | 2946 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 300 | 0.020 |
Why?
| | Clone Cells | 1 | 2013 | 263 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2013 | 45 | 0.020 |
Why?
| | Keratins | 1 | 2013 | 171 | 0.020 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2013 | 99 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 13 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.020 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 27 | 0.020 |
Why?
| | DNA, Viral | 1 | 2015 | 357 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 459 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2142 | 0.020 |
Why?
| | Mice, 129 Strain | 1 | 2012 | 85 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 615 | 0.020 |
Why?
| | Alveolar Epithelial Cells | 1 | 2013 | 121 | 0.020 |
Why?
| | Airway Remodeling | 1 | 2012 | 63 | 0.020 |
Why?
| | Regeneration | 1 | 2013 | 198 | 0.020 |
Why?
| | Epoprostenol | 1 | 2012 | 132 | 0.020 |
Why?
| | Blood Coagulation Factors | 1 | 2012 | 71 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 409 | 0.020 |
Why?
| | Pulmonary Eosinophilia | 1 | 2011 | 27 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 61 | 0.020 |
Why?
| | Connective Tissue Diseases | 1 | 2012 | 85 | 0.020 |
Why?
| | Sex Distribution | 1 | 2012 | 390 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 138 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2012 | 287 | 0.020 |
Why?
| | Cocarcinogenesis | 1 | 2010 | 13 | 0.020 |
Why?
| | Cytochromes | 1 | 2010 | 10 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2011 | 273 | 0.020 |
Why?
| | Receptors, Retinoic Acid | 1 | 2010 | 44 | 0.020 |
Why?
| | Endotoxins | 1 | 2011 | 217 | 0.020 |
Why?
| | alpha-Tocopherol | 1 | 2010 | 33 | 0.020 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 324 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 862 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2013 | 780 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1344 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2010 | 64 | 0.020 |
Why?
| | Spleen | 1 | 2012 | 509 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 552 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 120 | 0.020 |
Why?
| | Purpura | 1 | 2009 | 18 | 0.020 |
Why?
| | Homeostasis | 1 | 2013 | 651 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2009 | 41 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1302 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 80 | 0.020 |
Why?
| | Bacterial Infections | 1 | 2011 | 247 | 0.020 |
Why?
| | Granuloma | 1 | 2009 | 97 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2009 | 269 | 0.020 |
Why?
| | Binding Sites | 1 | 2012 | 1319 | 0.020 |
Why?
| | Elastin | 1 | 2009 | 78 | 0.020 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 237 | 0.020 |
Why?
| | Pulmonary Surfactants | 1 | 2009 | 105 | 0.020 |
Why?
| | Myoblasts | 1 | 2009 | 83 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2008 | 15 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 417 | 0.020 |
Why?
| | Testicular Neoplasms | 1 | 2009 | 111 | 0.020 |
Why?
| | Thrombosis | 1 | 2012 | 401 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 2012 | 522 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2008 | 306 | 0.020 |
Why?
| | Hepatitis C, Chronic | 1 | 2009 | 154 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 301 | 0.020 |
Why?
| | Phagocytosis | 1 | 2009 | 299 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 849 | 0.020 |
Why?
| | Lymphocytes | 1 | 2009 | 378 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2009 | 434 | 0.020 |
Why?
| | Precision Medicine | 1 | 2011 | 464 | 0.020 |
Why?
| | Survival Analysis | 1 | 2010 | 1386 | 0.020 |
Why?
| | RNA | 1 | 2013 | 916 | 0.020 |
Why?
| | Transfection | 1 | 2009 | 930 | 0.020 |
Why?
| | Photomicrography | 1 | 2006 | 8 | 0.020 |
Why?
| | Colectomy | 1 | 2007 | 107 | 0.020 |
Why?
| | Transcriptome | 1 | 2013 | 1059 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2007 | 167 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1266 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 330 | 0.020 |
Why?
| | Rare Diseases | 1 | 2007 | 116 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1046 | 0.010 |
Why?
| | Abdominal Pain | 1 | 2007 | 149 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2013 | 2054 | 0.010 |
Why?
| | MicroRNAs | 1 | 2012 | 694 | 0.010 |
Why?
| | Base Sequence | 1 | 2009 | 2175 | 0.010 |
Why?
| | Risk Factors | 1 | 2020 | 11017 | 0.010 |
Why?
| | Acute Disease | 1 | 2008 | 1049 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2009 | 784 | 0.010 |
Why?
| | Lung Transplantation | 1 | 2008 | 338 | 0.010 |
Why?
| | Colonoscopy | 1 | 2007 | 266 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1049 | 0.010 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2004 | 27 | 0.010 |
Why?
| | Weight Loss | 1 | 2009 | 867 | 0.010 |
Why?
| | Liver | 1 | 2012 | 1916 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1776 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2011 | 3027 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2008 | 745 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2006 | 794 | 0.010 |
Why?
| | Cytokines | 1 | 2009 | 2086 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 676 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2009 | 2812 | 0.010 |
Why?
| | Mutation | 1 | 2011 | 4130 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 5476 | 0.010 |
Why?
| | United States | 1 | 2011 | 16313 | 0.010 |
Why?
|
|
Groshong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|